Mirae Asset Global Investments Co. Ltd. Increases Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Mirae Asset Global Investments Co. Ltd. grew its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 25.9% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 374,762 shares of the company’s stock after purchasing an additional 77,186 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in AstraZeneca were worth $24,757,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. AQR Capital Management LLC increased its stake in AstraZeneca by 112.4% in the second quarter. AQR Capital Management LLC now owns 13,685 shares of the company’s stock valued at $1,067,000 after purchasing an additional 7,241 shares during the period. GAMMA Investing LLC grew its holdings in shares of AstraZeneca by 19.5% during the third quarter. GAMMA Investing LLC now owns 5,433 shares of the company’s stock worth $423,000 after buying an additional 887 shares during the last quarter. Fulton Bank N.A. increased its position in AstraZeneca by 2.3% in the 3rd quarter. Fulton Bank N.A. now owns 9,329 shares of the company’s stock valued at $727,000 after acquiring an additional 211 shares during the period. Chesley Taft & Associates LLC purchased a new stake in AstraZeneca during the 3rd quarter valued at approximately $1,287,000. Finally, Dynamic Advisor Solutions LLC lifted its position in AstraZeneca by 4.0% during the 3rd quarter. Dynamic Advisor Solutions LLC now owns 14,367 shares of the company’s stock worth $1,119,000 after acquiring an additional 551 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group raised shares of AstraZeneca from a “sell” rating to a “neutral” rating in a report on Wednesday, November 20th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Price Performance

AstraZeneca stock opened at $70.93 on Thursday. The company has a market cap of $219.96 billion, a P/E ratio of 33.94, a price-to-earnings-growth ratio of 1.18 and a beta of 0.46. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The business has a fifty day moving average of $67.20 and a two-hundred day moving average of $73.72. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating the consensus estimate of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter last year, the business earned $0.87 earnings per share. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. As a group, analysts predict that AstraZeneca PLC will post 4.13 earnings per share for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.